Mitochondrial dysfunction and drug targets in multiple myeloma

Multiple myeloma (MM) is the second most common hematological cancer that has no cure. Although currently there are several novel drugs, most MM patients experience drug resistance and disease relapse. The results of previous studies suggest that aberrant mitochondrial function may contribute to tumor progression and drug resistance. Mitochondrial DNA mutations and metabolic reprogramming have been reported in MM patients. Several preclinical and clinical studies have shown encouraging results of mitochondria-targeting therapy in MM patients. In this review, we have summarized our current understanding of mitochondrial biology in MM. More importantly, we have reviewed mitochondrial targeting strategies in MM treatment.

Automated summary

Multiple myeloma (MM) is a commonly occurring hematological cancer without a cure. Drug resistance and disease relapse are major challenges in MM treatment. Aberrant mitochondrial function, including DNA mutations and metabolic reprogramming, has been observed in MM patients. Mitochondria-targeting therapies have shown promising results in preclinical and clinical studies. This review summarizes our current knowledge of mitochondrial biology in MM and discusses strategies for targeting mitochondria in MM treatment.